Evidence map›Paper›PMID 32425085›Full record

ReviewSLAS discovery : advancing life sciences R & D2020

Secretome-Based Screening in Target Discovery.

Mei Ding, Hanna Tegel, Åsa Sivertsson, Sophia Hober, Arjan Snijder, Mats Ormö, Per-Erik Strömstedt, Rick Davies, Lovisa Holmberg Schiavone

Open access · bronzeAbstract readReview
In one paragraph

Review in SLAS discovery : advancing life sciences R & D, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Cancer secretome: finding out hidden messages in extracellular secretions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mei DingDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.ORCID https://orcid.org/0000-0001-8146-1535
Hanna TegelDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH, Royal Institute of Technology, Stockholm, Sweden.
Åsa SivertssonDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH, Royal Institute of Technology, Stockholm, Sweden.
Sophia HoberDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH, Royal Institute of Technology, Stockholm, Sweden.
Arjan SnijderDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Mats OrmöDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Per-Erik StrömstedtMechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Rick DaviesDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Lovisa Holmberg SchiavoneDiscovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
AstraZeneca (Sweden) · SEKTH Royal Institute of Technology · SEAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secreted proteins and their cognate plasma membrane receptors regulate human physiology by transducing signals from the extracellular environment into cells resulting in different cellular phenotypes. Systematic use of secretome proteins in assays enables discovery of novel biology and signaling pathways. Several secretome-based phenotypic screening platforms have been described in the literature and shown to facilitate target identification in drug discovery. In this review, we summarize the current status of secretome-based screening. This includes annotation, production, quality control, and sample management of secretome libraries, as well as how secretome libraries have been applied to discover novel target biology using different disease-relevant cell-based assays. A workflow for secretome-based screening is shared based on the AstraZeneca experience. The secretome library offers several advantages compared with other libraries used for target discovery: (1) screening using a secretome library directly identifies the active protein and, in many cases, its cognate receptor, enabling a rapid understanding of the disease pathway and subsequent formation of target hypotheses for drug discovery; (2) the secretome library covers significant areas of biological signaling space, although the size of this library is small; (3) secretome proteins can be added directly to cells without additional manipulation. These factors make the secretome library ideal for testing in physiologically relevant cell types, and therefore it represents an attractive approach to phenotypic target discovery.

Indexed as

High-Throughput Screening AssaysCellular MicroenvironmentDrug DiscoveryGene LibraryHumansProteomeProteomecell-based screeningphenotypic drug discoverysecretome librarytarget discovery

Identifiers

PMID32425085
PMCPMC7309359
OpenAlexW3028537558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.